Today: 21 April 2026
Nasdaq Partners With Kraken on Tokenized Stocks, Eyes 2027 Launch

Nasdaq Partners With Kraken on Tokenized Stocks, Eyes 2027 Launch

NEW YORK, March 9, 2026, 10:33 (EDT)

Nasdaq announced Monday it’s developing a new system for tokenized shares—those built on blockchain technology—and has enlisted Payward, the company behind crypto exchange Kraken, to help create the link between established stock markets and blockchain platforms.

This is significant at this moment, with a top U.S. exchange stepping further into tokenized equities only days after banking regulators decided lenders won’t face additional capital requirements for blockchain-based securities. SEC staff, back in January, stated that tokenized shares may be handled as traditional ones provided holders retain essentially the same rights and privileges.

Tokenization, basically, means converting an asset—like a share or bond—into a token on the blockchain. Nasdaq’s setup aims to let issuers retain control of things like proxy voting, dividends, and other actions, while tying blockchain data directly to the company’s official share ledger. Tal Cohen, president at Nasdaq, described the move as a step toward an “always-on financial ecosystem.” GlobeNewswire

Payward and Kraken plan to develop an equities transformation gateway using Kraken’s xStocks framework, aiming to let tokenized shares flow between regulated venues and public blockchains in jurisdictions where it’s allowed. Nasdaq is targeting the first half of 2027 for the launch. Arjun Sethi, co-CEO of Payward and Kraken, said the setup could open access in areas where “traditional distribution has been limited.” Kraken Blog

The Wall Street Journal says the framework is set to allow any willing issuer to join, even those that aren’t listed on Nasdaq. Kraken would handle distribution for customers across Europe and beyond the U.S. Token holders, according to the Journal, are slated to get governance rights mirroring those of traditional shareholders.

ICE, which owns the New York Stock Exchange, is pushing for regulatory sign-off on its blockchain-powered platform aimed at nonstop trading and settlement. Over in Europe, tokenized stocks are already live through Robinhood, Gemini, and Kraken. Coinbase and Dinari are moving forward with related offerings in the U.S.

Back in September, Nasdaq laid out its proposed regulatory approach in a filing to the SEC, seeking approval for listed stocks and exchange-traded products to trade either as traditional digital securities or as tokenized versions, all through Depository Trust & Clearing Corporation—the main U.S. clearing utility. Nasdaq’s filing made clear: tokenized instruments shouldn’t be considered on par with regular shares unless they offer identical material rights and protections.

But it’s still early days for the plan. Nasdaq’s September filing made clear that launching token-settled trading hinges on both SEC approval and the necessary market plumbing coming together. In January, SEC staff flagged concerns that certain third-party stock tokens could be classified as synthetic, price-linked products—not actual shares.

Stock Market Today

  • Sensex surges 753 points as US-Iran peace talks boost Indian markets
    April 21, 2026, 11:33 AM EDT. The Sensex jumped 753 points to 79,273.33 and the Nifty 50 crossed 24,550 amid growing optimism over US-Iran peace talks, easing crude oil prices, and strong earnings from key sectors. The market capitalization of BSE-listed companies rose by ₹3 lakh crore in one day, reaching nearly ₹469 lakh crore. Banking and FMCG stocks led the gains, with Nestle India, Hindustan Unilever, and Trent as top gainers. Sectoral indices like Nifty Bank and FMCG surged, while Pharma and Consumer Durables slipped slightly. Analysts said easing geopolitical tensions and falling crude prices lifted risk appetite, despite mid and small-cap segments underperforming. Investors remain focused on corporate earnings and global developments.

Latest article

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

21 April 2026
Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
POET Technologies Stock Soars Again as PFIC Tax Clarity Eases Short-Seller Fears

POET Technologies Stock Soars Again as PFIC Tax Clarity Eases Short-Seller Fears

21 April 2026
POET Technologies shares surged 20% Tuesday, following an 18% gain Monday, after the company addressed U.S. shareholder tax concerns and announced plans to redomicile. Nearly 32.9 million shares traded by 10:21 a.m. ET, with the stock reaching $11.07 before settling at $10.34. Wolfpack Research disclosed a short position last week, sparking volatility. CFO Thomas Mika said POET expects not to qualify as a PFIC in 2026.
Why Rocket Lab Stock Is Rising Again as Analysts Lift Targets and Golden Dome Spending Comes Into Focus

Why Rocket Lab Stock Is Rising Again as Analysts Lift Targets and Golden Dome Spending Comes Into Focus

21 April 2026
Rocket Lab shares rose 2% to $91.12 Tuesday after analysts raised price targets and the Pentagon detailed new space defense spending in its 2027 budget request. The company closed its $155 million Mynaric acquisition last week and reported a $190 million Pentagon launch contract in March, bringing its backlog above $2 billion. Rocket Lab now expects to launch its Neutron rocket in late 2026 after a test setback.
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now
Previous Story

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds
Next Story

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Go toTop